Atezolizumab (Tecentriq) is a humanized monoclonal antibody against PD-L1 developed by Genentech/Roche. The patent landscape for it is multi-layered and jurisdiction-specific, covering several broad areas:
What the patents generally cover
- Composition of matter / antibody sequence patents
- Patents claiming the atezolizumab antibody itself (heavy/light chain sequences, binding regions, and the defined mAb structure).
- Therapeutic use patents
- Methods of treating various cancers with atezolizumab (e.g., NSCLC, urothelial cancer, and other indications) and in specific combinations (with chemotherapy, other immunotherapies, etc.).
- Manufacturing, formulation, and process patents
- Ways of producing, purifying, or formulating the antibody.
- Diagnostics / companion tests
- Patents around PD-L1 detection assays and biomarker strategies used to select patients for atezolizumab therapy.
- Fc engineering and related technologies
- Patents covering Fc region properties or engineering to modify activity (if applicable to this molecule).
Key practical notes
- The patent picture is complex and involves many families across multiple countries. Some families may be expired or near expiry in certain jurisdictions, while others (especially use or combination patents) may still be in force in some markets.
- Regulatory exclusivities (e.g., data protection for biologics) are separate from patents and also affect market protection and entry of biosimilars.
- In many cases, freedom-to-operate analyses require checking dozens of families and their family-wide status (US, EU, UK, JP, CN, etc.).
How you can check the current status quickly
- Use patent databases to map families and statuses:
- Google Patents: search “atezolizumab” or “tecentriq” and open Patent Families to see all related patent documents by country.
- USPTO Patent Center (US), EPO Espacenet (EU), WIPO Patentscope (international), and national databases for each country.
- Look for terms like “composition of matter,” “antibody sequence,” “use,” “methods of treatment,” and “manufacturing” in the family titles.
- Key tasks when reviewing:
- Identify the earliest filing date and publication dates for the main antibody-structure patents.
- Check the legal status in each jurisdiction (expired, pending, granted, or lapsed).
- Note any term adjustments or pediatric/SPC data that extend protection in specific markets.
- Identify any biosimilar-related litigation or settlements that might influence entry timing.
If you’d like, I can perform a focused, jurisdiction-specific patent landscape check for atezolizumab (e.g., US and EU) and summarize:
- The main patent families (composition, use, manufacturing).
- Current legal status and approximate expiry windows per jurisdiction.
- Any active or recent litigation or licensing notes.
Tell me:
- Which jurisdiction(s) you care about (US, EU, Japan, others)?
- Whether you want a high-level landscape or a deeper, document-by-document status check?
- If you’re evaluating freedom-to-operate, licensing, or potential biosimilar entry.